Risk for colorectal cancer in ulcerative colitis: Changes, causes and management strategies

被引:322
作者
Lakatos, Peter Laszlo [1 ]
Lakatos, Laszlo [2 ]
机构
[1] Semmelweis Univ, Dept Med 1, Koranyi Str 2-A, H-4083 Budapest, Hungary
[2] Csolnoky F Cty Hosp, Dept Med 1, H-8201 Veszprem, Hungary
关键词
ulcerative colitis; colorectal cancer; risk factors; surveillance; chemprevention;
D O I
10.3748/wjg.14.3937
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The risk of colorectal cancer for any patient with ulcerative colitis is known to be elevated, and is estimated to be 2% after 10 years, 8% after 20 years and 18% after 30 years of disease. Risk factors for cancer include extent and duration of ulcerative colitis, primary sclerosing cholangitis, a family history of sporadic colorectal cancer, severity of histologic bowel inflammation, and in some studies, young age at onset of colitis. In this review, the authors discuss recent epidemiological trends and causes for the observed changes. Population-based studies published within the past 5 years suggest that this risk has decreased over time, despite the low frequency of colectomies. The crude annual incidence rate of colorectal cancer in ulcerative colitis ranges from approximately 0.06% to 0.16% with a relative risk of 1.0-2.75. The exact mechanism for this change is unknown; it may partly be explained by the more widespread use of maintenance therapy and surveillance colonoscopy. (C) 2008 The WJG Press. All rights reserved.
引用
收藏
页码:3937 / 3947
页数:11
相关论文
共 101 条
[71]   Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis [J].
Pardi, DS ;
Loftus, EV ;
Kremers, WK ;
Keach, J ;
Lindor, KD .
GASTROENTEROLOGY, 2003, 124 (04) :889-893
[72]   RISK-FACTORS FOR COLORECTAL-CANCER IN PATIENTS WITH ULCERATIVE-COLITIS - A CASE-CONTROL STUDY [J].
PINCZOWSKI, D ;
EKBOM, A ;
BARON, J ;
YUEN, J ;
ADAMI, HO .
GASTROENTEROLOGY, 1994, 107 (01) :117-120
[73]   Inflammation and colorectal cancer: IBD-associated and sporadic cancer compared [J].
Rhodes, JM ;
Campbell, BJ .
TRENDS IN MOLECULAR MEDICINE, 2002, 8 (01) :10-16
[74]   Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-γ [J].
Rousseaux, C ;
Lefebvre, B ;
Dubuquoy, L ;
Lefebvre, P ;
Romano, O ;
Auwerx, J ;
Metzger, D ;
Wahli, W ;
Desvergne, B ;
Naccari, GC ;
Chavatte, P ;
Farce, A ;
Bulois, P ;
Cortot, A ;
Colombel, JF ;
Desreumaux, P .
JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 201 (08) :1205-1215
[75]   DNA ANEUPLOIDY IN COLONIC BIOPSIES PREDICTS FUTURE-DEVELOPMENT OF DYSPLASIA IN ULCERATIVE-COLITIS [J].
RUBIN, CE ;
HAGGITT, RC ;
BURMER, GC ;
BRENTNALL, TA ;
STEVENS, AC ;
LEVINE, DS ;
DEAN, PJ ;
KIMMEY, M ;
PERERA, DR ;
RABINOVITCH, PS .
GASTROENTEROLOGY, 1992, 103 (05) :1611-1620
[76]   Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis? [J].
Rubin, David T. ;
Rothe, Jand A. ;
Hetzel, Jeremy T. ;
Cohen, Russell D. ;
Hanauer, Stephen B. .
GASTROINTESTINAL ENDOSCOPY, 2007, 65 (07) :998-1004
[77]   Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis [J].
Rubin, David T. ;
LoSavio, Andelka ;
Yadron, Nicole ;
Huo, Dezheng ;
Hanauer, Stephen B. .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2006, 4 (11) :1346-1350
[78]   The changing face of colorectal cancer in inflammatory bowel disease: Progress at last! [J].
Rubin, DT .
GASTROENTEROLOGY, 2006, 130 (04) :1350-1352
[79]   Will a 5-ASA a day keep the cancer (and dysplasia) away? [J].
Rubin, DT ;
Lashner, BA .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (06) :1354-1356
[80]   Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis [J].
Rutter, M ;
Saunders, B ;
Wilkinson, K ;
Rumbles, S ;
Schofield, G ;
Kamm, M ;
Williams, C ;
Price, A ;
Talbot, I ;
Forbes, A .
GASTROENTEROLOGY, 2004, 126 (02) :451-459